Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Evolus Inc EOLS

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.


NDAQ:EOLS - Post by User

Bullboard Posts
Next >>
Post by AviseAnalyticson Aug 04, 2023 8:30am
72 Views
Post# 35572816

EVOLUS: NEXT BIG THING IN THE PERFORMANCE BEAUTY INDUSTRY

EVOLUS: NEXT BIG THING IN THE PERFORMANCE BEAUTY INDUSTRY
$EOLS

Excited to share an article about Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products. The Company's product Jeuveau has been the fastest-growing neurotoxin in the U.S. for two consecutive years.

Evolus will expand its product portfolio to include a line of five different fillers beginning in 2025. The Company will likely achieve net revenues of $700 million by 2028, representing a 29% CAGR. This rapidly expanding Company serves a highly under-penetrated market and hence seems poised for exponential growth.
 
https://www.aviseanalytics.com/evolus-next-big-thing-in-the-performance-beauty-industry/

Bullboard Posts
Next >>